<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158073">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01913093</url>
  </required_header>
  <id_info>
    <org_study_id>1000033923</org_study_id>
    <nct_id>NCT01913093</nct_id>
  </id_info>
  <brief_title>N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors</brief_title>
  <acronym>N-PhenoGENICS</acronym>
  <official_title>N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Cancer Society Research Institute (CCSRI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>C17 Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Garron Family Cancer Center at the Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pediatric Oncology Group of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To find possible therapeutic targets to help prevent long-term brain and behavioural side
      effects in survivors of childhood leukemia that may have been caused by chemotherapy
      (Treatment-Related late Adverse Neuro-Cognitive Effects: TRANCE). The study hypothesis is
      that genetic variations of the elements in the folate-related cycles and methotrexate
      disposition networks are associated with the TRANCE phenotype of childhood leukemia
      survivors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To define neuro-cognitive/behavioural phenotypes of the childhood leukemia survivors</measure>
    <time_frame>100 participants assessed/year for 5 years.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the folate and vitamin B12 intakes of these children.</measure>
    <time_frame>&lt;100 participants assessed/year for 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To identify DNA methylation patterns associated with TRANCE trait in the leukemia survivors</measure>
    <time_frame>100 participants in 5 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Childhood Leukemia Survivors</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Leukemia survivors with TRANCE trait</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Leukemia survivors without TRANCE trait</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA samples obtained via blood, saliva and buccal sample collection.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Childhood leukemia survivors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Past diagnosis of acute lymphoblastic leukemia

          -  8 years : 0 months - 18 years : 11 months old at the time of their study visit

          -  2 years : 0 months - 10 years : 11 months from the last treatment for acute
             lymphoblastic leukemia at the time of their study visit

          -  Continuous complete remission and undergone no bone marrow transplantation

          -  Fluent in English (a subject and one parent) for test completion

          -  Signed informed consent

        Exclusion Criteria:

          -  Inability to complete the phenotyping tests

          -  Down Syndrome diagnosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Shinya Ito</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Sharon Guger</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Johann Hitzler</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Deborah L O'Connor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Russell Schachar</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Brenda Spiegler</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Rosanna Weksberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Vitti</last_name>
    <phone>416-813-8285</phone>
    <email>michelle.vitti@sickkids.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vitti</last_name>
      <phone>416-813-8285</phone>
      <email>michelle.vitti@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Shinya Ito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 29, 2013</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Shinya Ito</investigator_full_name>
    <investigator_title>Division Head, Clinical Pharmacology and Toxicology</investigator_title>
  </responsible_party>
  <keyword>Childhood leukemia survivors</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Late effects</keyword>
  <keyword>Folate</keyword>
  <keyword>Blood folate</keyword>
  <keyword>Neurotoxicity</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Cognitive late effects</keyword>
  <keyword>N-PhenoGENICS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
